Freya Pharma Solutions secures US$8.5 million enabling the start of a pivotal phase 3 trial with Lybrido against Female Sexual Interest/Arousal Disorder (FSIAD)

/PRNewswire/ -- Freya Pharma Solutions, a late clinical stage company focusing on the development of effective pharmaceutical therapies for women who have been...

Related Keywords

Helsinki ,Eteläuomen Läi ,Finland ,United States ,Netherlands ,Amsterdam ,Noord Holland ,American ,Marcel Wijma ,American Psychiatric Association ,Prnewswire Freya Pharma Solutions ,European Union ,Freya Pharma Solutions ,Lifespring Life Sciences Communication ,Pharma Solutions ,Female Sexual ,Arousal Disorder ,Scientific Advice Meeting ,Good Clinical Practices ,Trial Regulation ,Member States ,Executive Director ,Statistical Manual ,Mental Disorders ,Spring Life Sciences Communication ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,Women ,